Novavax (NVAX) Receivables - Net (2010 - 2026)

Novavax's Receivables - Net history runs 15 years deep, the most recent figure standing at $19.1 million for Q1 2026.

• In Q1 2026, Receivables - Net fell 63.4% year-over-year to $19.1 million; the TTM figure through Mar 2026 stood at $19.1 million (down 63.4% YoY), while the FY2025 annual figure was $106.4 million, down 1.7% from the prior year.
• Receivables - Net was $19.1 million for Q1 2026 at Novavax, down from $106.4 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $478.2 million in Q1 2022 to a low of $19.1 million in Q1 2026.
• Historically, Receivables - Net has averaged $159.6 million across 5 years, with a median of $111.6 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Receivables - Net soared 740.37% in 2022, then plunged 81.05% in 2024.
• A 5-year view of Receivables - Net shows it stood at $96.2 million in 2022, then soared by 216.93% to $304.9 million in 2023, then plunged by 64.49% to $108.3 million in 2024, then dropped by 1.7% to $106.4 million in 2025, then tumbled by 82.06% to $19.1 million in 2026.
• The last three Receivables - Net figures came in at $19.1 million (Q1 2026), $106.4 million (Q4 2025), and $34.2 million (Q3 2025), per Business Quant data.